Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13061-13068

  Zang, Na ^a,b   Xie, Xiaohong ^b   Deng, Yu ^b   Wu, Shengde ^b   Wang, Lijia ^a   Peng, Caijing ^a   Li, Simin ^a   Ni, Ke ^a   Luo, Yan ^a   Liu, Enmei ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PLACEBO; RESVERATROL; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; LUNG LAVAGE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GENE EXPRESSION PROFILING; INFLAMMATION; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SIGNAL TRANSDUCTION; STILBENES; TOLL-LIKE RECEPTOR 3; VIRAL LOAD;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84862944493     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05869-11     Document Type: Article

References (51)

1. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. 1998. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102:1211-1216.
2. Anonymous. 2004. Respiratory syncytial virus activity-United States, 2003-2004. MMWR Morb. Mortal. Wkly. Rep. 53:1159-1160.
3. Baatjes, A. J., et al. 2002. Anti-allergic therapies: effects on eosinophil progenitors. Pharmacol. Ther. 95:63-72.
4. Barczyk, A., W. Pierzchala, and E. Sozanska. 2003. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97:726-733.
5. Bennett, B. L., et al. 2007. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 195:1532-1540.
6. Blackwell, T. S., and J. W. Christman. 1997. The role of nuclear factorkappa B in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 17:3-9.
7. Boeck, K. D. 1996. Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Monaldi Arch. Chest Dis. 51:210-213.
8. Bradamante, S., L. Barenghi, and A. Villa. 2004. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 22:169-188.
9. Buckner, C. K., V. Songsiridej, E. C. Dick, and W. W. Busse. 1985. In vivo and in vitro studies on the use of the guinea pig as a model for virusprovoked airway hyperreactivity. Am. Rev. Respir. Dis. 132:305-310.
10. Burstein, B., et al. 2007. Effects of resveratrol (trans-3,5,4 -trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther. 323:916-923.
11. Docherty, J. J., et al. 2005. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res. 67:155-162.
12. Docherty, J. J., T. J. Sweet, E. Bailey, S. A. Faith, and T. Booth. 2006. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res. 72:171-177.
13. Evers, D. L., X. Wang, S. M. Huong, D. Y. Huang, and E. S. Huang. 2004. 3,4 ,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res. 63:85-95.
14. Faith, S. A., T. J. Sweet, E. Bailey, T. Booth, and J. J. Docherty. 2006. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res. 72:242-251.
15. Falsey, A. R., P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759.
16. Fryer, A. D., and D. B. Jacoby. 1991. Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the guinea-pig. Br. J. Pharmacol. 102:267-271.
17. Fryer, A. D., and J. Maclagan. 1984. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br. J. Pharmacol. 83:973-978.
18. Graham, B. S., L. A. Bunton, P. F. Wright, and D. T. Karzon. 1991. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88:1026-1033.
19. Groskreutz, D. J., et al. 2006. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J. Immunol. 176:1733-1740.
20. Haeberle, H. A., et al. 2002. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and Tolllike receptor 4-dependent pathways. J. Infect. Dis. 186:1199-1206.
21. Hain, R., B. Bieseler, H. Kindl, G. Schroder, and R. Stocker. 1990. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol. 15:325-335.
22. Haynes, L. M., et al. 2001. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75:10730-10737.
23. Hellings, P. W., et al. 2003. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 28:42-50.
24. Henderson, W. R., Jr., et al. 1997. Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. 100:3083-3092.
25. Henderson, W. R., Jr., J. Lu, K. M. Poole, G. N. Dietsch, and E. Y. Chi. 2000. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J. Immunol. 164:3360-3367.
26. Holmes-McNary, M., and A. S. Baldwin, Jr. 2000. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60:3477-3483.
27. Jacoby, D. B., H. Q. Xiao, N. H. Lee, Y. Chan-Li, and A. D. Fryer. 1998. Virus- and interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J. Clin. Invest. 102:242-248.
28. Jang, M., et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
29. Kim, H. W., et al. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
30. Kong, X., et al. 2005. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Virol. J. 2:3.
31. Lee, M., et al. 2009. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int. Immunopharmacol. 9:418-424.
32. Leung, D. Y., and S. J. Szefler. 1998. New insights into steroid resistant asthma. Pediatr. Allergy Immunol. 9:3-12.
33. Lin, J. F., et al. 2008. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 83:313-317.
34. Liu, P., et al. 2007. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virusinfected airway epithelial cells. J. Virol. 81:1401-1411.
35. Manna, S. K., A. Mukhopadhyay, and B. B. Aggarwal. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NFkappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164:6509-6519.
36. McKimm-Breschkin, J. L. 2004. A simplified plaque assay for respiratory syncytial virus-direct visualization of plaques without immunostaining. J. Virol. Methods 120:113-117.
37. Morishima, H., K. Kajiwara, K. Akiyama, and Y. Yanagihara. 2008. Ligation of Toll-like receptor 3 differentially regulates M2 and M3 muscarinic receptor expression and function in human airway smooth muscle cells. Int. Arch. Allergy Immunol. 145:163-174.
38. Myou, S., et al. 2003. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J. Exp. Med. 198:1573-1582.
39. Negishi, H., et al. 2008. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc. Natl. Acad. Sci. U. S. A. 105:20446-20451.
40. Newton, R. 2000. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55:603-613.
41. Newton, R., L. M. Kuitert, M. Bergmann, I. M. Adcock, and P. J. Barnes. 1997. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem. Biophys. Res. Commun. 237:28-32.
42. Palamara, A. T., et al. 2005. Inhibition of influenza A virus replication by resveratrol. J. Infect. Dis. 191:1719-1729.
43. Paramore, L. C., V. Ciuryla, G. Ciesla, and L. Liu. 2004. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22:275-284.
44. Polack, F. P., et al. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196:859-865.
45. Rudd, B. D., E. Burstein, C. S. Duckett, X. Li, and N. W. Lukacs. 2005. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J. Virol. 79:3350-3357.
46. Rudd, B. D., et al. 2006. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J. Immunol. 176:1937-1942.
47. Tsai, S. H., S. Y. Lin-Shiau, and J. K. Lin. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126:673-680.
48. Welliver, R. C. 2003. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J. Pediatr. 143:S112-S117.
49. Xie, X. H., et al. 2009. Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the Toll-like receptor 4 signaling pathway. Pediatr. Res. 65:156-162.
50. Yang, M., R. K. Kumar, and P. S. Foster. 2010. Interferon-gamma and pulmonary macrophages contribute to the mechanisms underlying prolonged airway hyperresponsiveness. Clin. Exp. Allergy 40:163-173.
51. Youn, H. S., et al. 2005. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 175:3339-3346.